- Lab Automation Market: Premium Industry Insights.
This report aims to provide detailed insights into the global lab automation market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Expected Revenue Growth:
The lab automation market size will grow to USD 5.5 billion by 2025 from USD 4.3 billion in 2020, at a CAGR of 5.2% during the forecast period.
Download PDF Brochure:
Key Factors Driving Market Growth:
The Increasing spending on pharmaceutical R&D, growing food safety concerns, standardization of workflows, stringent regulatory control in the healthcare industry are fuelling the growth of the market. Moreover, high demand in the emerging nation and the growth of the pharmaceutical and biotechnology industries are some of the other major factors driving the growth of this market.
The Automated Workstations segment is expected to dominate the lab automation market, by product type, during the forecast period.
Automated workstations are compact & standalone, capable of conducting a particular task unattended. Owing to the easy integration with both existing and upcoming systems are favorable options for customers looking to introduce automation in their labs. The Automated workstations is further segmented to automated liquid handling systems, microplate reader, automated Elisa system, automated nucleic acid purification systems. The automated liquid handling system are growing at the highest CAGR. Owing to an increase in the number of tests carried out in pharmaceutical labs for screening compounds, optimizing leads, determining drug properties with absorption, distribution, metabolism, and excretion (ADME), and toxicity has favored the argument for automation.
The drug discovery is expected to be the fastest-growing lab automation market, by application, during the forecast period.
The drug discovery, by application, laboratory automation market is estimated to grow at the fastest rate during the forecast period. This is mainly because of the increasing industry-academia collaboration for the development and use of fully automated, ultrahigh-throughput systems. Moreover, investments in automation permit the safer generation of data with improved accuracy, precision, reproducibility, and traceability, allowing drug discovery scientists to utilize higher–quality data in the hypothesis–driven research required to discover new medicines. Thus, growing the market of drug discovery segment.
Request For Sample Pages:
North America likely to emerge as the largest lab automation market
In this report, the laboratory automation market has been analyzed for four regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Growth in the North American market is also supported by the demand for the integration of laboratory systems, rising government funding for research, growth in biobanks, need for early drug discovery, and stringent regulatory requirements. Thus, North America dominated the market during the forecasted period.
To enable an in-depth understanding of the competitive landscape, the report includes the profiles of some of the top players in the market.
Some of the key players are Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc,(US) Agilent Technologies (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), and Tecan Group Ltd. (Switzerland).The leading players are adopting various strategies to increase their share in the lab automation market.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.